Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry

• DOI: 10.1371/journal.pone.0250820
• Publication Date: 2021-05-18T17:23:11Z
• Authors: Viktoria Papp; Mathias Due Buron; Volkert Siersma; Peter Vestergaard...; Zsolt Illes; Matthias Kant; Claudia Hilt; Zsolt Mezei; Homayoun Roshanis...; Tobias Sejbæk; Arkadiusz Weglewski; Janneke van Winge...; Svend Sparre Geer...; Stephan Bramow; Finn Sellebjerg; Melinda Magyari
• Keywords: Teriflunomide; Discontinuation

Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in real-world setting involving population-based large cohort unselected patients enrolled The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013–2019. Methods This was complete nationwide study with prospectively cases. Demographic and disease-specific patient parameters related to history, efficacy outcomes, discontinuation switching rates among other variables were assessed at baseline during follow-up visits. Results A total 3239 (65.4% female) the period, 56% whom treatment-naïve. Compared previously treated patients, treatment-naïve older on average disease onset, had shorter duration, lower Expanded Disability Status Scale score start more frequently experienced relapse 12 months prior initiation. In 3001 initiating least before cut-off date, 72.7% still one year after start. Discontinuations first due mainly adverse events (15.6%). Over full 47.5% discontinued treatment. Sixty-three percent 5 years relapse-free, while significantly versus (p<0.0001). Furthermore, 85% available data free disability worsening end follow-up. Conclusions Solid persistence consistent studies obtained over period. Treatment this scenario support previous findings that an effective generally well-tolerated DMT MS mild moderate activity.